Discussing the practice and management of continuing education in precision medicine_West China Medical Journal

Authors：

WANG Denian ¹ , YANG Zhi ² , CHEN Bojiang ¹ ,  LI Weimin ¹

1. Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
2. Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

LI Weimin, Email: weimi003@scu.edu.cn

Keywords：

Precision medicine; genetic testing; diagnosis and treatment mode; continuing education; clinical practice and management

DOI：

10.7507/1002-0179.202306175

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Precision medicine is a medical paradigm founded on individual genetic information amalgamated with extensive clinical data to offer patients precise diagnoses and treatments. Genetic testing forms the cornerstone of accurate diagnosis, and skilled professionals in fields like clinical medicine, molecular biology, and bioinformatics play a crucial role in realizing the potential of precision medicine. This paper presents reference suggestions for the continuing education approach for relevant technical personnel. The main emphasis is on conducting routine face-to-face and hands-on training to enhance theoretical knowledge and professional skills. Secondly, there is a need to modify the training approach by reinforcing molecular biology, bioinformatics, and other courses, enhancing assessment methods, gradually implementing specialized training in precision medicine subspecialties, and ensuring effective clinical practice and management of precision medicine.

Citation： WANG Denian, YANG Zhi, CHEN Bojiang, LI Weimin. Discussing the practice and management of continuing education in precision medicine. West China Medical Journal, 2023, 38(8): 1128-1132. doi: 10.7507/1002-0179.202306175 Copy

1.	Møller RS, Hammer TB, Rubboli G, et al. From next-generation sequencing to targeted treatment of non-acquired epilepsies. Expert Rev Mol Diagn, 2019, 19(3): 217-228.
2.	Kim J, Hu C, Moufawad El Achkar C, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med, 2019, 381(17): 1644-1652.
3.	Denny JC, Collins FS. Precision medicine in 2030-seven ways to transform healthcare. Cell, 2021, 184(6): 1415-1419.
4.	Ramaswami R, Bayer R, Galea S. Precision medicine from a public health perspective. Annu Rev Public Health, 2018, 39: 153-168.
5.	Olson MV. Precision medicine at the crossroads. Hum Genomics, 2017, 11(1): 23.
6.	Matthew DB. Two threats to precision medicine equity. Ethn Dis, 2019, 29(Suppl 3): 629-640.
7.	National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington D. C. : National Academies Press (US), 2011.
8.	Johnson KB, Wei WQ, Weeraratne D, et al. Precision medicine, AI, and the future of personalized health care. Clin Transl Sci, 2021, 14(1): 86-93.
9.	König IR, Fuchs O, Hansen G, et al. What is precision medicine?. Eur Respir J, 2017, 50(4): 1700391.
10.	Hayden EC. Technology: the $1, 000 genome. Nature, 2014, 507(7492): 294-295.
11.	Nakagawa H, Fujita M. Whole genome sequencing analysis for cancer genomics and precision medicine. Cancer Sci, 2018, 109(3): 513-522.
12.	Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
13.	Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448(7153): 561-566.
14.	Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.
15.	Madeddu C, Donisi C, Liscia N, et al. EGFR-mutated non-small cell lung cancer and resistance to immunotherapy: role of the tumor microenvironment. Int J Mol Sci, 2022, 23(12): 6489.
16.	Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet, 2018, 50(9): 1219-1224.
17.	Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J, 2019, 53(5): 1900164.
18.	McGrath S, Ghersi D. Building towards precision medicine: empowering medical professionals for the next revolution. BMC Med Genomics, 2016, 9(1): 23.
19.	Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med, 2017, 19(2): 249-255.
20.	Freeley M. Current postgraduate training programs and online courses in precision medicine. Expert Rev Mol Diagn, 2020, 20(6): 569-574.
21.	Murphy MJ, Shahriari N, Payette M, et al. Development of a curriculum in molecular diagnostics, genomics and personalized medicine for dermatology trainees. J Cutan Pathol, 2016, 43(10): 858-865.

1. Møller RS, Hammer TB, Rubboli G, et al. From next-generation sequencing to targeted treatment of non-acquired epilepsies. Expert Rev Mol Diagn, 2019, 19(3): 217-228.
2. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med, 2019, 381(17): 1644-1652.
3. Denny JC, Collins FS. Precision medicine in 2030-seven ways to transform healthcare. Cell, 2021, 184(6): 1415-1419.
4. Ramaswami R, Bayer R, Galea S. Precision medicine from a public health perspective. Annu Rev Public Health, 2018, 39: 153-168.
5. Olson MV. Precision medicine at the crossroads. Hum Genomics, 2017, 11(1): 23.
6. Matthew DB. Two threats to precision medicine equity. Ethn Dis, 2019, 29(Suppl 3): 629-640.
7. National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington D. C. : National Academies Press (US), 2011.
8. Johnson KB, Wei WQ, Weeraratne D, et al. Precision medicine, AI, and the future of personalized health care. Clin Transl Sci, 2021, 14(1): 86-93.
9. König IR, Fuchs O, Hansen G, et al. What is precision medicine?. Eur Respir J, 2017, 50(4): 1700391.
10. Hayden EC. Technology: the $1, 000 genome. Nature, 2014, 507(7492): 294-295.
11. Nakagawa H, Fujita M. Whole genome sequencing analysis for cancer genomics and precision medicine. Cancer Sci, 2018, 109(3): 513-522.
12. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
13. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448(7153): 561-566.
14. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.
15. Madeddu C, Donisi C, Liscia N, et al. EGFR-mutated non-small cell lung cancer and resistance to immunotherapy: role of the tumor microenvironment. Int J Mol Sci, 2022, 23(12): 6489.
16. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet, 2018, 50(9): 1219-1224.
17. Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J, 2019, 53(5): 1900164.
18. McGrath S, Ghersi D. Building towards precision medicine: empowering medical professionals for the next revolution. BMC Med Genomics, 2016, 9(1): 23.
19. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med, 2017, 19(2): 249-255.
20. Freeley M. Current postgraduate training programs and online courses in precision medicine. Expert Rev Mol Diagn, 2020, 20(6): 569-574.
21. Murphy MJ, Shahriari N, Payette M, et al. Development of a curriculum in molecular diagnostics, genomics and personalized medicine for dermatology trainees. J Cutan Pathol, 2016, 43(10): 858-865.

West China Medical Journal

Discussing the practice and management of continuing education in precision medicine

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content